Announcements
I'm Back and Speaking at DIA on February 22
02/09/11 22:26
Oh boy, well, I haven't done a blog post since last November (last November 2010!), and it was all about Social Media regulation in the wake of FDA's public meeting on electronic and social media. And Oh boy, well, where's that guidance document everyone is clamoring for? That's the speed of FDA. If you're new to paying attention to FDA's guidance or rule making productivity, this is about the pace you get. I'm not saying FDA is being lazy or slow either, but the process is slow, is fraught with competing priorities and other administrative gauntlets. Moreover, industry lack of prolific use of new social media technologies really isn't harming anyone, so I'd say I'm certain FDA has bigger priorities on any given day.
Enough about FDA, sometimes this site is just about me. And me explaining myself. I've been terribly busy. It was a crazy year being a regulatory person. And yes, I did work on some social media stuff, but most of my work was dealing with lots of other issues largely unrelated to social media. So be it. I didn't blog. I didn't tweet (much) and didn't really pay attention to any tweets or blogs. And, you know what? I don't feel any less informed or less connected to my world and my clients. Wait...I do confess...I pay attention to the Pharmalot blog, a lot. Thanks Ed for getting back on track.
I do want to tell you though that I'll be making a rare public appearance at the DIA meeting in Washington in two weeks hosting a panel of esteemed colleagues to discuss FDA regulation of health economic information and the rise of comparative effectiveness research. This is a super great topic. In fact, I think it may be the single most important regulatory topic over the next decade. A case of regulatory policy, public and private interest, and Federal Legislation all at war with one another. I'll share my thoughts soon on this blog, but in the meantime if you're at the DIA meeting, come to our panel discussion on the 22nd of February.
So anyway, I'm back, somewhat embarrassed by my lack of blogging, and remain fully committed to being more prolific on this site if time permits and if I have the energy and initiative. How's that for commitment?
JM
Enough about FDA, sometimes this site is just about me. And me explaining myself. I've been terribly busy. It was a crazy year being a regulatory person. And yes, I did work on some social media stuff, but most of my work was dealing with lots of other issues largely unrelated to social media. So be it. I didn't blog. I didn't tweet (much) and didn't really pay attention to any tweets or blogs. And, you know what? I don't feel any less informed or less connected to my world and my clients. Wait...I do confess...I pay attention to the Pharmalot blog, a lot. Thanks Ed for getting back on track.
I do want to tell you though that I'll be making a rare public appearance at the DIA meeting in Washington in two weeks hosting a panel of esteemed colleagues to discuss FDA regulation of health economic information and the rise of comparative effectiveness research. This is a super great topic. In fact, I think it may be the single most important regulatory topic over the next decade. A case of regulatory policy, public and private interest, and Federal Legislation all at war with one another. I'll share my thoughts soon on this blog, but in the meantime if you're at the DIA meeting, come to our panel discussion on the 22nd of February.
So anyway, I'm back, somewhat embarrassed by my lack of blogging, and remain fully committed to being more prolific on this site if time permits and if I have the energy and initiative. How's that for commitment?
JM
0 Comments